Expertise in
1
conditions

Dr. Andrew J. Wagner

Emergency Medicine
Mercy Hospital
1010 Three Springs Blvd, 
Durango, CO 
Accepting New Patients
Referral may be required
Before you request
Expertise in
1
conditions
Mercy Hospital
1010 Three Springs Blvd, 
Durango, CO 

Overview

Andrew Wagner is an Emergency Medicine provider practicing medicine in Durango, Colorado.

Dr. Wagner is highly rated in 1 condition, according to our data. His clinical expertise encompasses Non-Muscle Invasive Bladder Cancer, Tissue Biopsy, and Prostatectomy.

He is actively involved in clinical research, co-authoring 155 peer reviewed articles and participating in 10 clinical trials. Dr. Wagner is currently accepting new patients.

Specialties

Emergency Medicine

Licenses

Emergency Medicine in OH

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID

Locations

Mercy Hospital
1010 Three Springs Blvd, Durango, CO 81301
Other Locations
STAT Doctors Medical Group LTD.
4535 Dressler Rd NW, Canton, OH 44718

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2026
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Drug
Study Drugs: Olaratumab, Pembrolizumab
Study Phase: Phase 1
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: TP-1287
Study Phase: Phase 1
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)
A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)
Enrollment Status: Completed
Publish Date: August 31, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 8 Less Clinical Trials

155 Total Publications

Adjuvant chemotherapy vs. observation for locally advanced upper tract urothelial carcinoma following radical nephroureterectomy.
Adjuvant chemotherapy vs. observation for locally advanced upper tract urothelial carcinoma following radical nephroureterectomy.
Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: September 01, 2026
Similar Doctors
Expertise in
1
conditions
Dr. Brett G. Ziercher
Emergency Medicine
Expertise in
1
conditions
Dr. Brett G. Ziercher
Emergency Medicine
Referral may be required
Before you request

San Juan Regional Medical Center

801 W Maple St, 
Farmington, NM 
 (41.5 miles away)
505-325-5011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brett Ziercher is an Emergency Medicine provider practicing medicine in Farmington, New Mexico. Dr. Ziercher is highly rated in 1 condition, according to our data. His clinical expertise encompasses End-Stage Renal Disease (ESRD) and Liver Failure. Dr. Ziercher is currently accepting new patients.

Expertise in
1
conditions
Dr. Catherine A. Ambrose
Emergency Medicine
Expertise in
1
conditions
Dr. Catherine A. Ambrose
Emergency Medicine
Referral may be required
Before you request

San Juan Regional Medical Center

801 W Maple St, 
Farmington, NM 
 (41.5 miles away)
505-609-6102
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Catherine Ambrose is an Emergency Medicine provider practicing medicine in Farmington, New Mexico. Dr. Ambrose is highly rated in 1 condition, according to our data. Her clinical expertise encompasses End-Stage Renal Disease (ESRD) and Gallbladder Disease. Dr. Ambrose is currently accepting new patients.

Expertise in
1
conditions
Dr. Jenny R. Hargrove
Emergency Medicine
Expertise in
1
conditions
Dr. Jenny R. Hargrove
Emergency Medicine
Referral may be required
Before you request
801 W Maple St, 
Farmington, NM 
 (41.5 miles away)
505-609-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Jenny Hargrove is an Emergency Medicine provider practicing medicine in Farmington, New Mexico. Dr. Hargrove is highly rated in 1 condition, according to our data. Her clinical expertise encompasses End-Stage Renal Disease (ESRD) and Endoscopy. Dr. Hargrove is currently accepting new patients.

Frequently Asked Questions about Dr. Andrew J. Wagner

How do I make an appointment with Dr. Andrew J. Wagner?

You can book an appointment with Dr. Andrew J. Wagner by calling their office at 970-247-4311. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrew J. Wagner a top-rated expert for Tissue Biopsy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrew J. Wagner is classified as an Advanced expert for Tissue Biopsy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrew J. Wagner specialize in?

While Dr. Andrew J. Wagner is a Emergency Medicine, they have specific expertise in Tissue Biopsy, Non-Muscle Invasive Bladder Cancer, and Prostatectomy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Emergency Medicine.

Does Dr. Andrew J. Wagner participate in research or clinical trials?

Yes. Dr. Andrew J. Wagner has published 155 articles and abstracts on conditions like Tissue Biopsy. You can view a list of Dr. Andrew J. Wagner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Andrew J. Wagner accept my insurance?

Dr. Andrew J. Wagner accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 970-247-4311 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wagner's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile